首页> 美国卫生研究院文献>Oncogenesis >Identification of differentially expressed miRNAs in individual breast cancer patient and application in personalized medicine
【2h】

Identification of differentially expressed miRNAs in individual breast cancer patient and application in personalized medicine

机译:个体乳腺癌患者差异表达miRNA的鉴定及其在个性化医学中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

MicroRNAs (miRNAs) have key roles in breast cancer progression, and their expression levels are heterogeneous across individual breast cancer patients. Traditional methods aim to identify differentially expressed miRNAs in populations rather than in individuals and are affected by the expression intensities of miRNAs in different experimental batches or platforms. Thus it is urgent to conduct miRNA differential expression analysis at an individual level for further personalized medicine research. We proposed a straightforward method to determine the differential expression of each miRNA in an individual patient by utilizing the reversal expression order of miRNA pairs between two conditions (cancer and normal tissue). We applied our method to breast cancer miRNA expression profiles from The Cancer Genome Atlas and two other independent data sets. In total, 292 miRNAs were differentially expressed in individual breast cancer patients. Using the differential expression profile of miRNAs in individual patients, we found that the deregulations of miRNA tend to occur in specific breast cancer subtypes. We investigated the coordination effect between the miRNA and its target, based on the hypothesis that one gene function can be changed by copy number alterations of the corresponding gene or deregulation of the miRNA. We revealed that patients exhibiting an upregulation of hsa-miR-92b and patients with deletions of PTEN did not tend to overlap, and hsa-miR-92b and PTEN coordinately regulated the pathway of ‘cell cycle' and so on. Moreover, we discovered a new prognostic signature, hsa-miR-29c, whose downregulation was associated with poor survival of breast cancer patients.
机译:MicroRNA(miRNA)在乳腺癌的进展中具有关键作用,并且它们的表达水平在各个乳腺癌患者之间是异质的。传统方法旨在鉴定人群中而不是个体中差异表达的miRNA,并且受不同实验批次或平台中miRNA表达强度的影响。因此,迫切需要在个体水平上进行miRNA差异表达分析,以进行进一步的个性化医学研究。我们提出了一种简单的方法来确定单个患者中每个miRNA的差异表达,方法是利用两个条件(癌症和正常组织)之间的miRNA对的反向表达顺序。我们将我们的方法应用于《癌症基因组图谱》和其他两个独立数据集的乳腺癌miRNA表达谱。总共292个miRNA在个体乳腺癌患者中差异表达。使用个别患者中miRNA的差异表达谱,我们发现miRNA的失调倾向于发生在特定的乳腺癌亚型中。我们基于一种假设,即一种基因功能可以通过相应基因的拷贝数改变或miRNA的失控来改变,从而研究了miRNA及其靶标之间的协同作用。我们发现,表现出hsa-miR-92b上调的患者和PTEN缺失的患者没有重叠的趋势,hsa-miR-92b和PTEN协同调节“细胞周期”等途径。此外,我们发现了一种新的预后标志,hsa-miR-29c,其下调与乳腺癌患者的不良生存有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号